Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate

British Journal of Pharmacology

Volumn 125, Issue 7, 1998, Pages 1610-1616

  Della Paschoa, O E ^a   Voskuyl, R A ^b   Danhof, M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b Instituut voor Epilepsiebestrijding   (Netherlands)

Author keywords

Cortical stimulation; Drug interaction; Phenytoin; PK PD modelling; Sodium valproate

Indexed keywords

PHENYTOIN; VALPROIC ACID;

ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ELIMINATION; DRUG INFUSION; DRUG POTENCY; DRUG PROTEIN BINDING; GRAND MAL SEIZURE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICHAELIS MENTEN KINETICS; NONHUMAN; PHARMACODYNAMICS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT; STEADY STATE;

EID: 0031793233     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702235     Document Type: Article

References (55)

1. BARRE, J., DIDEY, F., DELION, F. & TILLEMENT, J.P. (1988). Problems in therapeutic drug monitoring: free drug level monitoring. Ther. Drug. Monit., 10, 133-143.
2. BRODIE, M.J. (1992). Drug interactions in epilepsy. Epilepsia, 33 (Suppl 1), S13-S22.
3. BROWN, S.W. & SHOKRY, A. (1997). Erfahrungen in Großbritannien mit Add-on Therapien bei Epilepsie. Schweiz. Rundsch Med. Prax.., 86, 1426-1429.
4. BRUNI, J., GALLO, J.M., LEE, C.S., PERCHALSKI, R.J. & WILDER, B.J. (1980). Interactions of valproic acid and phenytoin. Neurology, 30, 1233-1236.
5. BRUNI, J., WILDER, B.J., WILLMORE, I.J. & BARBOUR, B. (1979). Valproic acid and plasma levels of serum phenytoin. Neurology, 29, 904-905.
6. CHEZ, M.G., BOURGEOIS, B.F., PIPPENGER, C.E. & KNOWLES, W.D. (1994). Pharmacodynamic interactions between phenytoin and valproate: individual and combined antiepileptic and neurotoxic actions in mice. Clin. Neuropharmacol., 17, 32-37.
7. CLOYD, J. (1991). Pharmacokinetic pitfalls of present antiepileptic medications. Epilepsia, 32 (Suppl 5), S53-S65.
8. CRAMER, J.A. & MATTSON, R.H. (1979). Valproic acid: in vitro plasma protein binding and interaction with phenytoin. Ther, Drug Monit., 1, 105-116.
9. DANHOF, M., VOSKUYL, R.A. & HOOGERKAMP, A. (1992). Pharmacokinetic-pharmacodynamic modelling with anticonvulsants in animal models and in humans. In: The in vivo study of drug action, (eds). Boxtel, C.J., Holford, N.H.G. & Danhof, M. pp. 179-201. Amsterdam: Elsevier Science Publishers B.V.
10. DELLA PASCHOA O.E., KRUK, M.R., HAMSTRA, R., VOSKUYL, R.A. & DANHOF, M. (1998a). Pharmacodynamic interaction between phenytoin and sodium valproate changes seizure threshold and pattern. Br. J. Pharmacol., (in press).
11. DELLA PASCHOA, O.E., MANDEMA, J.W., VOSKUYL, R.A. & DANHOF, M. (1998b). Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant and EEG effects of phenytoin in rats. J. Pharmacol. Exp. Ther., 284, 460-466.
12. DILL, W.A., KAZENKO, A., WOLFF, L.M. & GLAZKO, A.J. (1956). Studies on 5,5-diphenylhydantoin (dilantin) in animals and in man. J. Pharmacol. Exp. Ther., 118, 270-279.
13. DUROZARD, D. & BAVAREL, G. (1987). Gas Chromatographic method for the measurement of sodium valproate utilization by kidney tubules. J. Chromatogr., 414, 460-464.
14. GIBALDI, M. & PERRIER, D. (1982). Nonlinear pharmacokinetics. In: Pharmacokinets, 271-318. New York: Marcel Dekker Inc.
15. GOMEZ BELLVER, M.J., GARCIA SANCHEZ, M.J., ALONSO GONZALEZ, A.C., SANTOS BUELGA, D. & DOMINGUEZ-GIL. A (1993). Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. J. Clin. Pharm. Ther., 18, 191-197.
16. GRAVES, N.M. (1993). Pharmacokinetics and interactions of antiepileptic drugs. Am. J. Hosp. Pharm., 50 (Suppl 5), S23-S29.
17. GUMBLETON, M , OIE, S. & VEROTTA, D (1994). Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences. Br. J. Clin. Pharmacol., 38, 389-400.
18. HOLFORD, N.H. (1990). Concepts and usefulness of pharmacokinetic-pharmacodynamic modelling. Fundam. Clin. Pharmacol., 4, 93s-101s.
19. HOOGERKAMP, A., VIS, P.W., DANHOF, M. & VOSKUYL, R.A. (1994). Characterization of the pharmacodynamics of several antiepileptic drugs in a direct cortical stimulation model of anticonvulsant effect in the rat. J. Pharmacol. Exp. Ther., 269, 521-528.
20. HOSFORD, D.A., CADDICK, S.J. & LIN, F.H. (1997). Generalized epilepsies: emerging insights into cellular and genetic mechanisms. Curr. Opin. Neurol., 10, 115-120.
21. JOHNSON, G.J., KILPATRICK, C.J., BURY, R.W., FULLINFAW. R.O. & MOULDS, R.F. (1989). Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate-the predictive value of plasma albumin concentration. Br. J. Clin. Pharmacol., 27, 843-849.
22. KUTT, H. (1995). Phenytoin. Interactions with other drugs: clinical aspects. In: Antiepileptic drugs, 4th Edn. (eds). Levy, R.H., Mattson, R.H. & Meldrum, B.S. pp. 315-328. New York: Raven Press, Ltd.
23. LEVY, R.H. & BAJPAI, M. (1995). Phenytoin. Interaction with other drugs: mechanistic aspects. In: Antiepileptic drugs, 4th Edn. (eds). Levy, R.H., Mattson, R.H. & Meldrum, B.S. pp. 329-338. New York: Raven Press, Ltd.
24. LEVY, R.H. & KOCH, M. (1982). Drug interactions with valproic acid. Drugs, 24, 543-556.
25. LOLIN, Y.I., RATNARAJ, N., HJELM, M. & PATSALOS, P.N. (1994). Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: phenytoin. Epilepsy Res., 19, 99-110.
26. LÖSCHER, W. (1998). New visions in the pharmacology of anti-convulsion. Eur. J. Pharmacol., 342, 1-13.
27. LUCKOW, V. & DELLA PASCHOA, O.E. (1997). PK/PD modelling of high-dose diltiazem-absorption-rate dependency of the hysteresis loop. Int. J. Clin. Pharmacol. Ther., 35, 418-425.
28. MANDEMA. J.W., SANSOM, L.N., DIOS-VIEITEZ, MC., HOLLANDER-JANSEN, M & DANHOF, M. (1991a). Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J. Pharmacol. Exp. Ther., 257, 472-478.
29. MANDEMA, J.W., VENG-PEDERSEN, P & DANHOF, M. (1991b). Estimation of ambarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions. J. Pharmacokinet. Biopharm., 19, 617-634.
30. MAY, T & RAMBECK, R. (1990). Fluctuation of unbound and total phenytoin concentrations during the day in epileptic patients on valproic acid comedication. Ther. Drug. Monit., 12, 124-128.
31. MONKS, A. & RICHENS, A. (1980). Effects of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients. Clin. Pharmacol. Ther., 27, 89-95.
32. NATION, R L., EVANS, A.M. & MILNE, R.W. (1990). Pharmacokinetic drug interactions with phenytoin (Part I). Clin. Pharmacokinet., 18, 37-60.
33. NOSEK, T.M. (1981). How valproate and phenytoin affect the ionic conductances and active transport characteristics of the crayfish giant axon. Epilepsia, 22, 651-665.
34. PATSALOS. P.N. & DUNCAN, J.S. (1993). Antiepileptic drugs. A review of clinically significant drug interactions. Drug Saf., 9, 156-184.
35. PISANI, F, PERUCCA, E. & DI PERRI, R. (1990). Clinically relevant anti-epileptic drug interactions. J. Int. Med. Res., 18, 1-15.
36. RAGSDALE, D.S. & AVOLI, M. (1998). Sodium channels as molecular targets for antiepileptic drugs. Brain Res. Rev., 26, 16-28.
37. RAMBECK, B., SPECHT, U. & WOLF. P. (1996). Pharmacokinetic interactions of the new antiepileptic drugs. Clin. Pharmacokinet., 31, 309-324.
38. RAMSAY, R.E., HAMMOND, E.J., PERCHALSKI, R.J. & WILDER. B.J. (1979). Brain uptake of phenytoin, phenobarbital, and diazepam. Arch. Neurol., 36, 535-539.
39. RAMZAN, I. & LEVY, G. (1989). Relationship between concentration and anticonvulsant effect of phenytoin against electroshock-induced seizures in rats: comparison of sampling sites of concentration determinations. J. Pharm. Sci., 78, 448-451.
40. REIFE, R.A. (1998). Assessing pharmacokinetic and pharmacodynamic interactions in clinical trials of antiepileptic drugs. Adv. Neurol., 76, 95-103.
41. RIVA, R, ALBANI, F., CONTIN, M. & BARUZZI, A. (1996). Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin. Pharmacokinet., 31, 470-493.
42. SCHEYER, R.D., CRAMER, J.A., TOFTNESS, BR. HOCHHOLZER, J.M. & MATTSON. RH (1990). In vivo determination of valproate binding constants during sole and multi-drug therapy. Ther. Drug. Monit., 12, 117-123.
43. SCHEYER, R.D. & MATTSON, RH (1991). A method for prediction of phenytoin levels in the acute clinical setting. Comput. Biomed. Res., 24, 564-575.
44. SCHEYER, R.D. & MATTSON, R.H (1995). Valproic acid. Interactions with other drugs. In: Antiepileptic drugs. 4th Edn. (eds). Levy, R.H., Mattson, R.H. & Meldrum, B.S. pp.621-631. New York: Raven Press, Ltd.
45. SCHEYER, R.D. & MATTSON, R.H. (1997). Protein binding and whole blood assays. Ther. Drug Monit., 19, 246.
46. SECHI, G.P., PETRUZZI, V., ROSATI, G., TANCA, S., MONACO, F., FORMATO, M., RUBATTU, L. & DE RIU, P. (1989). Brain interstitial fluid and intracellular distribution of phenytoin. Epilepsia, 30, 235-239.
47. SEGAL, M.M. & DOUGLAS, A.F. (1997). Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. J. Neurophysiol., 77, 3021-3034.
48. TOKOLA, R.A. & NEUVONEN, P.J. (1983). Pharmacokinetics of antiepileptic drugs. Acta. Neurol. Scand. Suppl., 97, 17-27.
49. TUK, B., DANHOF, M. & MANDEMA, J.W. (1997). The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates. J. Pharmacokinet. Biopharm., 25, 39-62.
50. TUK, B., HERBEN, V.M., MANDEMA, J.W. & DANHOF, M. (1998). Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. J. Pharmacol. Exp. Ther., 284, 202-207.
51. VENG-PEDERSEN, P, MANDEMA, J.W. & DANHOF, M. (1991). Biophase equilibration times. J. Pharm. Sci. 80, 881-886.
52. VOSKUYL, R.A., DINGEMANSE, J. & DANHOF, M. (1989). Determination of the threshold for convulsions by direct cortical stimulation. Epilepsy Res., 3, 120-129.
53. VOSKUYL, R.A., HOOGERKAMP, A. & DANHOF, M. (1992). Properties of the convulsive threshold determined by direct cortical stimulation in rats. Epilepsy Res., 12, 111-120.
54. WILDER, B.J. & HOMAN, R.W. (1996). Definition of rational antiepileptic polypharmacy. Epilepsy Res. Suppl., 11, 253-258.
55. WILLOW, M., GONOI, T. & CATTERALL, W.A. (1985). Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol. Pharmacol., 27, 549-558.